Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies

por Naymagon, Leonard, Mascarenhas, John
Publicado 2017

Novel therapeutics in myeloproliferative neoplasms

por Venugopal, Sangeetha, Mascarenhas, John
Publicado 2020

Next Generation Therapeutics for the Treatment of Myelofibrosis

por Tremblay, Douglas, Mascarenhas, John
Publicado 2021

The odyssey of pacritinib in myelofibrosis

por Venugopal, Sangeetha, Mascarenhas, John
Publicado 2022

A smoking gun? Clonal expansion in response to cigarette exposure

por Nathan, Daniel I., Mascarenhas, John
Publicado 2023

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes

por Mascarenhas, John O., Verstovsek, Srdan
Publicado 2022

CNL and aCML are prognostically distinct: a large National Cancer Database analysis

por Tremblay, Douglas, Sastow, Dahniel, Mascarenhas, John
Publicado 2023

Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia

por Lancman, Guido, Mascarenhas, John, Bar-Natan, Michal
Publicado 2020

Clinical Utility of Fedratinib in Myelofibrosis

por Waksal, Julian A, Tremblay, Douglas, Mascarenhas, John
Publicado 2021

Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies

por Mascarenhas, John, Roper, Nitin, Chaurasia, Pratima, Hoffman, Ronald
Publicado 2011

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor

por Tremblay, Douglas, Dougherty, Mikaela, Mascarenhas, John, Gallagher, Emily Jane
Publicado 2023

Complement-dependent Clearance of Apoptotic Cells by Human Macrophages

por Mevorach, Dror, Mascarenhas, John O., Gershov, Debra, Elkon, Keith B.
Publicado 1998

An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives...

por Qin, Albert, Urbanski, Raymond W., Yu, Lennex, Ahmed, Tasfia, Mascarenhas, John
Publicado 2023

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety

por Verstovsek, Srdan, Mesa, Ruben A., Livingston, Robert A., Hu, Wilson, Mascarenhas, John
Publicado 2023

Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges

por Ajufo, Helen O., Waksal, Julian A., Mascarenhas, John O., Rampal, Raajit K.
Publicado 2023

Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis

por Al-Fayoumi, Suliman, Hashiguchi, Taishi, Shirakata, Yuka, Mascarenhas, John, Singer, Jack W
Publicado 2018

Outcomes of COVID-19 Infection in Patients Receiving Ruxolitinib and Hypomethylating Agent Therapy

por Nathan, Daniel I., Tremblay, Douglas, Thibaud, Santiago, Mascarenhas, John, Gabrilove, Janice L.
Publicado 2020

The Latest Breakthroughs in Immunotherapy for Acute Myeloid Leukemia, with a Special Focus on NKG2D Ligands

por Maurer, Stefanie, Zhong, Xiaoxuan, Prada, Betsy Deza, Mascarenhas, John, de Andrade, Lucas Ferrari
Publicado 2022

Telomerase-targeted therapies in myeloid malignancies

por Waksal, Julian A., Bruedigam, Claudia, Komrokji, Rami S., Jamieson, Catriona H. M., Mascarenhas, John O.
Publicado 2023

PB2224: ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY

por Mascarenhas, John, He, Lei, Saab, Rabih, Gabrail, Nashat, Kirito, Keita, Brackman, Deanna, Innocenti, Federico
Publicado 2023